ArticleClinical and experimental medicine2026
DNA methylation biomarkers associated with early gastric cardia carcinogenesis.
Article in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Gastric cardia cancer (GCC) is an aggressive malignancy with poor prognosis, underscoring the need for better characterization of molecular alterations during early gastric cardia carcinogenesis. This study aimed to identify and validate tissue-based DNA methylation markers associated with early precancerous and neoplastic lesions of the gastric cardia. We integrated genome-wide DNA methylation data (850 K array) from 69 gastric cardia samples, including normal mucosa (n = 22), intestinal metaplasia (IM, n = 32), intraepithelial neoplasia (IEN, n = 7), and GCC (n = 8). Differential methylation analysis revealed stage-specific methylation patterns. Machine learning algorithms, including Least Absolute Shrinkage and Selection Operator (LASSO) regression and Random Forest, were used to refine candidate diagnostic biomarkers, followed by immunohistochemical validation of candidate gene expression in an independent cohort (n = 212). GCC progression showed increasing epigenetic dysregulation, with hyper-differentially methylated probes (DMPs) predominating in precancerous lesions (79.3-86.3%) and hypo-DMPs in GCC (87.7%). Hyper-DMPs were enriched in promoter-associated cytosine-phosphate-guanosine (CpG) islands (P < 0.001). Two DMPs, EDNRB_cg04390523 and SALL1_cg09016242, were consistently identified by both algorithms and showed good diagnostic accuracy (AUC = 0.947, 95% CI: 0.897-0.997) for distinguishing precancerous gastric cardia lesions and GCC from normal tissue in the integrated dataset. Consistent with methylation findings, EDNRB protein expression progressively decreased from normal to IM/IEN tissues (P < 0.001). This study identifies EDNRB and SALL1 promoter hypermethylation as promising tissue-based candidate biomarkers associated with early neoplastic transformation and provides a basis for further longitudinal and translational studies in gastric cardia precancerous lesions and cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.